- Home
- VANI vs MIRM Comparison
VANI vs MIRM Comparison
Compare VANI & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VANI
- MIRM
- Stock Information
- Founded
- VANI 1998
- MIRM 2018
- Country
- VANI United States
- MIRM United States
- Employees
- VANI N/A
- MIRM N/A
- Industry
- VANI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- VANI Health Care
- MIRM Health Care
- Exchange
- VANI Nasdaq
- MIRM Nasdaq
- Market Cap
- VANI N/A
- MIRM 1.9B
- IPO Year
- VANI 2014
- MIRM 2019
- Fundamental
- Price
- VANI $1.05
- MIRM $41.31
- Analyst Decision
- VANI Strong Buy
- MIRM Strong Buy
- Analyst Count
- VANI 1
- MIRM 11
- Target Price
- VANI $4.00
- MIRM $58.55
- AVG Volume (30 Days)
- VANI 92.8K
- MIRM 437.9K
- Earning Date
- VANI 05-12-2025
- MIRM 05-12-2025
- Dividend Yield
- VANI N/A
- MIRM N/A
- EPS Growth
- VANI N/A
- MIRM N/A
- EPS
- VANI N/A
- MIRM N/A
- Revenue
- VANI N/A
- MIRM $336,888,000.00
- Revenue This Year
- VANI N/A
- MIRM $29.51
- Revenue Next Year
- VANI N/A
- MIRM $20.27
- P/E Ratio
- VANI N/A
- MIRM N/A
- Revenue Growth
- VANI N/A
- MIRM 80.76
- 52 Week Low
- VANI $0.91
- MIRM $23.83
- 52 Week High
- VANI $2.09
- MIRM $54.23
- Technical
- Relative Strength Index (RSI)
- VANI 50.23
- MIRM 47.80
- Support Level
- VANI $1.02
- MIRM $38.22
- Resistance Level
- VANI $1.05
- MIRM $39.87
- Average True Range (ATR)
- VANI 0.03
- MIRM 2.08
- MACD
- VANI 0.01
- MIRM 0.34
- Stochastic Oscillator
- VANI 68.42
- MIRM 70.54
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.